FutureChem Obtains MFDS Approval for Prostate Cancer Diagnostic Agent "Prostview Injection"
Radiopharmaceutical for Diagnosing Recurrence and Metastasis
Pursuing Insurance Coverage and Expanded Indications
FutureChem has obtained approval for a new radiopharmaceutical for the diagnosis of prostate cancer.
According to industry sources on May 4, FutureChem announced via a disclosure that its Positron Emission Tomography (PET) diagnostic agent, Prostview Injection (compound name: Florastamin), has received product approval from the Ministry of Food and Drug Safety. The approval date is April 30, 2026. The application for this product was submitted on July 10, 2025.
Prostview Injection is a diagnostic drug used to more accurately identify lesions in patients with recurrent or metastatic prostate cancer who have shown abnormal findings in previous imaging tests.
This product can be used not only for definitive diagnosis to confirm the presence of lesions, but also for initial staging and restaging in recurrent patients. In particular, it is expected to help establish treatment strategies by enabling early detection of micrometastases and to reduce unnecessary treatments caused by false positives.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The company plans to consider whether the product will be covered by national health insurance and to conduct post-marketing surveillance and additional clinical studies to evaluate diagnostic accuracy and safety in real clinical settings. Through these efforts, FutureChem aims to explore the potential for expanding indications.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.